BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15837980)

  • 1. Pentostatin in steroid-refractory acute graft-versus-host disease.
    Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC; Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB
    J Clin Oncol; 2005 Apr; 23(12):2661-8. PubMed ID: 15837980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.
    Jacobsohn DA; Chen AR; Zahurak M; Piantadosi S; Anders V; Bolaños-Meade J; Higman M; Margolis J; Kaup M; Vogelsang GB
    J Clin Oncol; 2007 Sep; 25(27):4255-61. PubMed ID: 17878478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
    Margolis J; Vogelsang G
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin.
    Klein SA; Bug G; Mousset S; Hofmann WK; Hoelzer D; Martin H
    Br J Haematol; 2011 Jul; 154(1):143-6. PubMed ID: 21477160
    [No Abstract]   [Full Text] [Related]  

  • 7. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
    Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
    Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
    Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
    Prasad VK; Lucas KG; Kleiner GI; Talano JA; Jacobsohn D; Broadwater G; Monroy R; Kurtzberg J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):534-41. PubMed ID: 20457269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
    Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
    Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
    Foss FM
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.
    Schmitt T; Luft T; Hegenbart U; Tran TH; Ho AD; Dreger P
    Bone Marrow Transplant; 2011 Apr; 46(4):580-5. PubMed ID: 20562925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
    Bordigoni P; Dimicoli S; Clement L; Baumann C; Salmon A; Witz F; Feugier P
    Br J Haematol; 2006 Nov; 135(3):382-5. PubMed ID: 16984386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.
    Piñana JL; Valcárcel D; Martino R; Moreno ME; Sureda A; Briones J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2006 Nov; 12(11):1135-41. PubMed ID: 17085306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
    Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
    J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
    Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M
    Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
    Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.